D.E. Shaw & Co
THRX

D.E. Shaw & Co’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

D.E. Shaw & Co’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,412
Closed -$58K – 5649
2022
Q2 		$58K Buy
+10,412
New +$86K ﹤0.01% 4821
2022
Q1 		– Sell
-22,136
Closed -$281K – 6085
2021
Q4 		$281K Buy
+22,136
New +$334K ﹤0.01% 4715

Other funds holding THRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

D.E. Shaw & Co's THRX Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q3 2022, closing a stake of 10,412 shares — an estimated $58K sold.

D.E. Shaw & Co first reported a position in THRX in Q4 2021 and held it in 2 quarters. The position peaked at $281K in Q4 2021. 51 funds tracked by Wall St. Rank hold THRX as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,412 Theseus Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $58K.
  • D.E. Shaw & Co first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $281K in Q4 2021.
  • 51 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.